Announcements Trials
Browse Landscape

Phase

Phase 3 3

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3

Conditions

Carcinoma, Non-Small-Cell Lung 51Prostatic Neoplasms 23Lung Neoplasms 17Breast Neoplasms 15Squamous Cell Carcinoma of Head and Neck 13Stomach Neoplasms 10Parkinson Disease 4, Autosomal Dominant Lewy Body 8Neoplasms 8Urinary Bladder Neoplasms 6Carcinoma, Transitional Cell 6Triple Negative Breast Neoplasms 5Non-Muscle Invasive Bladder Neoplasms 5Neoplasm Metastasis 5Head and Neck Neoplasms 5Carcinoma, Squamous Cell 5Prostatic Neoplasms, Castration-Resistant 4Ovarian Neoplasms 4Oropharyngeal Neoplasms 4Endometrial Neoplasms 4Small Cell Lung Carcinoma 3Salivary Gland Neoplasms 3Nasopharyngeal Carcinoma 3Laryngeal Neoplasms 3HER2-positive Breast Cancer 3Fallopian Tube Neoplasms 3Anatomic Stage I Breast Cancer AJCC v8 3Adenocarcinoma 3Solid Tumors 2Sarcoma 2Osteosarcoma 2

Interventions

Paclitaxel 24Bevacizumab 21Carboplatin 20liposomal doxorubicin 15Specimen Handling 14Magnetic Resonance Spectroscopy 13olaparib 12Gemcitabine 10Topotecan 9pembrolizumab 8Biopsy 8Taxes 7Immunoglobulin G 6Disulfides 6niraparib 5Doxorubicin 5mirvetuximab soravtansine 4cediranib 4oregovomab 3Nivolumab 3Drug Therapy 3Docetaxel 3Cisplatin 3sarilumab 2rucaparib 2cemiplimab 2berzosertib 2adavosertib 2Saline Solution 2Platinum 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Fallopian Tube Neoplasms × Docetaxel × 90 days × Clear all
NCT03740165 2026-05-04

KEYLYNK-001

Merck Sharp & Dohme LLC

Phase 3 Completed
1,367 enrolled 29 charts
Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT05281471 2026-03-18

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

Genelux Corporation

Phase 3 Recruiting
186 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Vaccinia

NCT05116189 2026-03-09

KEYNOTE-B96

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
643 enrolled 17 charts 1 FDA
Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡